| Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS? | OTTAWA (dpa-AFX) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which... ► Artikel lesen |
| Kymera Therapeutics, Inc.: Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026 | BROADEN2 enrollment completed nearly six months ahead of anticipated timelines KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected... ► Artikel lesen |
| Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors | Bruce Booth, DPhil, Co-Founder and Chairman, to remain an Independent Director WATERTOWN, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical... ► Artikel lesen |
| Bicara Therapeutics Inc.: Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-ß Inhibition in 1L R/M HPV-Negative HNSCC | At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a... ► Artikel lesen |
| Bicara Therapeutics Inc.: Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow-up... ► Artikel lesen |
| Bicara Therapeutics Inc.: Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent loading... ► Artikel lesen |
| Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. | - Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE... ► Artikel lesen |
| Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1) | - Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage... ► Artikel lesen |
| Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen resulted in a robust... ► Artikel lesen |